In the above-mentioned time-course study of RAF/MEK inhibition resistance using scRNA-seq datasets from the melanoma PDX model, over 600 single cells were profiled across four time points: T0 (tumor before treatment), phase 1 (tumor shrinking stage after treatment), phase 2 (minimal residual disease stage), and phase 3 (relapsed stage after drug treatment) [36]. The gene discussed is MAP2K7; the disease is melanoma.